SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB: A REAL-LIFE STUDY ON MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Mangiacavalli, S. [1 ]
Cocito, F. [1 ]
Ferretti, V. [1 ]
Cartia, C. [1 ]
Cazzola, M. [1 ,2 ]
Corso, A. [1 ]
机构：
[1] IRCCS Fdn Policlin San Matteo, Hematol, Pavia, Italy
[2] Univ Pavia, Fdn Policlin San Matteo, Hematol, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1294
引用
收藏
页码：519 / 519
页数：1
相关论文
共 50 条
  • [1] A SINGLE CENTRE REAL LIFE EXPERIENCE ON MULTIPLE MYELOMA (MM) PATIENTS: SUBCUTANEOUS (SUBQ) VERSUS INTRAVENOUS (IV) BORTEZOMIB (BOR)
    Infante, M. S.
    Gonzalez, I.
    Munoz, C.
    Heras, C.
    Foncillas, M. A.
    Marin, K.
    Hernandez, J. A.
    [J]. HAEMATOLOGICA, 2016, 101 : 802 - 803
  • [2] Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
    Moreau, Philippe
    Coiteux, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    van de Velde, Helgi
    Acharya, Milin
    Harousseau, Jean-Luc
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1908 - 1911
  • [3] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients:a Meta-analysis
    牟时代
    艾利莎
    秦铀
    胡豫
    [J]. Current Medical Science, 2018, 38 (01) : 43 - 50
  • [4] SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A SINGLE INSTITUTION
    Lopez San Roman, I.
    De Miguel, D.
    Golbano, N.
    Diaz Morfa, M.
    Morales, D.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    Pinedo, B.
    [J]. HAEMATOLOGICA, 2012, 97 : 603 - 603
  • [5] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
    Shi-dai Mu
    Li-sha Ai
    You Qin
    Yu Hu
    [J]. Current Medical Science, 2018, 38 : 43 - 50
  • [6] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
    Mu, Shi-dai
    Al, Li-sha
    Qin, You
    Hu, Yu
    [J]. CURRENT MEDICAL SCIENCE, 2018, 38 (01) : 43 - 50
  • [7] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [8] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
    Zhang, Shilong
    Li, Jing
    Liu, Peng
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
  • [9] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    Arnulf, Bertrand
    Pylypenko, Halyna
    Groslcki, Sebastian
    Karamanesht, Ievgenii
    Leleu, Xavier
    van de Velde, Helgi
    Feng, Huaibao
    Cakana, Andrew
    Deraedt, William
    Moreau, Philippe
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12): : 1925 - 1928
  • [10] Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma
    Philippe Moreau
    Ievgenii I. Karamanesht
    Natalia Domnikova
    Maryna Y. Kyselyova
    Kateryna V. Vilchevska
    Vadim A. Doronin
    Alexander Schmidt
    Cyrille Hulin
    Xavier Leleu
    Dixie-Lee Esseltine
    Karthik Venkatakrishnan
    Donna Skee
    Huaibao Feng
    Suzette Girgis
    Andrew Cakana
    Helgi van de Velde
    William Deraedt
    Thierry Facon
    [J]. Clinical Pharmacokinetics, 2012, 51 : 823 - 829
12345